CTRI/2012/10/003065已完成3 期
Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®. - PROTECT-2
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sandoz GmbH
- 入组人数
- 302
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. histologically proven breast cancer
- •2. eligible for six cycles of neoadjuvant or adjuvant chemotherapy
排除标准
- •1. History of cancer
- •2. Active infection
- •3. Known immunodeficiency syndrome
- •4. Previous therapy with any G-CSF (granulocyte-colony stimulating factor) product
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®Breast CancerEUCTR2012-002039-28-ESSandoz GmbH308
招募中
不适用
A study to estimate improvement in quality of life, cost effectiveness of radiotherapy in patients of breast cancer with bone metastases.CTRI/2018/03/012317Tata Memorial Hospital
已完成
不适用
Evaluation of a Pilot Breast Cancer Survivorship Care Plan in New ZealandBreast cancer survivorship care planCancer - BreastBreast cancerACTRN12612001175864Regional Cancer Treatment Service, MidCentral Health DHB30
未知
不适用
PIVOTAL STUDY IN PATIENTS WITH BREAST CANCER TO INVESTIGATE THE EFFICACY AND SAFETY OF LA-EP2006 and NEULASTA ®PER-119-11Sandoz GmbH,
撤回
不适用
A randomised controlled trial of breast cancer patients treated with chemotherapy in a hospital day unit or at home; an analysis of cost and patient reported outcomesCancer - BreastPublic Health - Health service researchBreast cancerACTRN12615000197538A/Prof Suzanne Robinson130